OR23 HLA class II genes correlate with protective neutralizing antibody titers in a dengue vaccine efficacy trial

2018 ◽  
Vol 79 ◽  
pp. 29
Author(s):  
Aviva Geretz ◽  
Shida Shangguan ◽  
Chris Bryant ◽  
Philip Ehrenberg ◽  
Merlin Robb ◽  
...  
Keyword(s):  
Vaccine Efficacy ◽  
Neutralizing Antibody ◽  
Class Ii ◽  
Hla Class Ii ◽  
Efficacy Trial ◽  
Dengue Vaccine ◽  
Antibody Titers

scholarly journals HLA class II diversity in HIV-1 uninfected individuals from the placebo arm of the RV144 Thai vaccine efficacy trial

2015 ◽  
Vol 85 (2) ◽  
pp. 117-126 ◽  
Author(s):  
K. M. Baldwin ◽  
P. K. Ehrenberg ◽  
A. Geretz ◽  
H. A. Prentice ◽  
S. Nitayaphan ◽  
...  
Keyword(s):  
Vaccine Efficacy ◽  
Class Ii ◽  
Hla Class Ii ◽  
Efficacy Trial ◽  
Hiv 1

Immune Correlates Identified in the RV144 Vaccine Efficacy Trial Impact HIV-1 Acquisition Only in the Presence of Certain HLA Class II Genes

2014 ◽  
Vol 30 (S1) ◽  
pp. A40-A40
Author(s):  
Heather Prentice ◽  
Daniel Geraghty ◽  
Georgia D. Tomaras ◽  
Youyi Fong ◽  
Wyatt Nelson ◽  
...  
Keyword(s):  
Vaccine Efficacy ◽  
Class Ii ◽  
Hla Class Ii ◽  
Efficacy Trial ◽  
Immune Correlates ◽  
Hiv 1 ◽  
Rv144 Vaccine

scholarly journals Prediction of vaccine efficacy of the Delta variant

2021 ◽  
Author(s):  
Xinhua Chen ◽  
Andrew S. Azman ◽  
Wanying Lu ◽  
Ruijia Sun ◽  
Nan Zheng ◽  
...  
Keyword(s):  
Vaccine Efficacy ◽  
Protective Efficacy ◽  
Adenovirus Vector ◽  
Neutralizing Antibody ◽  
Effective Vaccine ◽  
Public Health Decision ◽  
Additional Tool ◽  
Health Decision Making ◽  
Health Decision ◽  
Antibody Titers

AbstractThe emergence of SARS-CoV-2 variants have raised concerns over the protective efficacy of the current generation of vaccines, and it remains unclear to what extent, if any, different variants impact the efficacy and effectiveness of various SARS-CoV-2 vaccines. We systematically searched for studies of SARS-CoV-2 vaccine efficacy and effectiveness, as well as neutralization data for variants, and used a previously published statistical model to predict vaccine efficacy against variants. Overall, we estimate the efficacy of mRNA-1273 and ChAdOx1 nCoV-19 against infection caused by the Delta variant to be 25-50% lower than that of prototype strains. The predicted efficacy against symptomatic illness of the mRNA vaccines BNT162b2 and mRNA-1273 are 95.1% (UI: 88.4-98.1%) and 80.8% (60.7-92.3%), respectively, which are higher than that of adenovirus-vector vaccines Ad26.COV2.S (44.8%, UI: 29.8-60.1%) and ChAdOx1 nCoV-19 (41.1%, 19.8-62.8%). Taken together, these results suggest that the development of more effective vaccine strategies against the Delta variant may be needed. Finally, the use of neutralizing antibody titers to predict efficacy against variants provides an additional tool for public health decision making, as new variants continue to emerge.

scholarly journals Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America

2017 ◽  
Vol 217 (5) ◽  
pp. 742-753 ◽  
Author(s):  
Zoe Moodie ◽  
Michal Juraska ◽  
Ying Huang ◽  
Yingying Zhuang ◽  
Youyi Fong ◽  
...  
Keyword(s):  
Latin America ◽  
Vaccine Efficacy ◽  
Neutralizing Antibody ◽  
Dengue Vaccine ◽  
Efficacy Trials

scholarly journals Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical Trial

2020 ◽  
Author(s):  
Leyi Lin ◽  
Michael A Koren ◽  
Kristopher M Paolino ◽  
Kenneth H Eckels ◽  
Rafael De La Barrera ◽  
...  
Keyword(s):  
Immune Responses ◽  
Dengue Virus ◽  
Phase 1 ◽  
Vaccination Strategy ◽  
Neutralizing Antibody ◽  
Dengue Vaccine ◽  
Serious Adverse Events ◽  
Live Attenuated Vaccine ◽  
Antibody Titers ◽  
Global Health Problem

Abstract Background Dengue is a global health problem and the development of a tetravalent dengue vaccine with durable protection is a high priority. A heterologous prime-boost strategy has the advantage of eliciting immune responses through different mechanisms and therefore may be superior to homologous prime-boost strategies for generating durable tetravalent immunity. Methods In this phase 1 first-in-human heterologous prime-boost study, 80 volunteers were assigned to 4 groups and received a tetravalent dengue virus (DENV-1–4) purified inactivated vaccine (TDENV-PIV) with alum adjuvant and a tetravalent dengue virus (DENV-1–4) live attenuated vaccine (TDENV-LAV) in different orders and dosing schedules (28 or 180 days apart). Results All vaccination regimens had acceptable safety profiles and there were no vaccine-related serious adverse events. TDEN-PIV followed by TDEN-LAV induced higher neutralizing antibody titers and a higher rate of tetravalent seroconversions compared to TDEN-LAV followed by TDEN-PIV. Both TDEN-PIV followed by TDEN-LAV groups demonstrated 100% tetravalent seroconversion 28 days following the booster dose, which was maintained for most of these subjects through the day 180 measurement. Conclusions A heterologous prime-boost vaccination strategy for dengue merits additional evaluation for safety, immunogenicity, and potential for clinical benefit. Clinical Trials Registration NCT02239614.

Dengue vaccine efficacy trial: does interference cause failure?

2013 ◽  
Vol 13 (3) ◽  
pp. 191-192 ◽  
Author(s):  
Sathyamangalam Swaminathan ◽  
Navin Khanna ◽  
Belinda Herring ◽  
Suresh Mahalingam
Keyword(s):  
Vaccine Efficacy ◽  
Efficacy Trial ◽  
Dengue Vaccine

Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction

Vaccine ◽  
2016 ◽  
Vol 34 (24) ◽  
pp. 2707-2712 ◽  
Author(s):  
Eric Plennevaux ◽  
Arunee Sabchareon ◽  
Kriengsak Limkittikul ◽  
Pornthep Chanthavanich ◽  
Chukiat Sirivichayakul ◽  
...  
Keyword(s):  
Vaccine Efficacy ◽  
Serological Testing ◽  
Efficacy Trial ◽  
Dengue Vaccine ◽  
Efficacy Evaluation ◽  
Vaccine Introduction

scholarly journals Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants

2021 ◽  
Author(s):  
Takuya Tada ◽  
Hao Zhou ◽  
Marie I Samanovic ◽  
Belinda M Dcosta ◽  
Amber Cornelius ◽  
...  
Keyword(s):  
Vaccine Efficacy ◽  
Adenoviral Vector ◽  
Neutralizing Antibody ◽  
Significant Fraction ◽  
Vector Vaccine ◽  
Antibody Titers

The increasing prevalence of SARS-CoV-2 variants has raised concerns regarding possible decreases in vaccine efficacy. Here, neutralizing antibody titers elicited by mRNA-based and an adenoviral vector-based vaccine against variant pseudotyped viruses were compared. BNT162b2 and mRNA-1273-elicited antibodies showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants whereas Ad26.COV2.S-elicited antibodies from a significant fraction of vaccinated individuals were of low neutralizing titer (IC50 <50). The data underscore the importance of surveillance for breakthrough infections that result in severe COVID-19 and suggest the benefit of a second immunization following Ad26.COV2.S to increase protection against the variants.

Sign in / Sign up

Export Citation Format

Share Document